Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

The surge in popularity of drugs like Ozempic, driven in part by its weight loss benefits, is contributing to a record-high ...

The letter indicates that Novo Nordisk already has 55% of the market for diabetes and obesity through its blockbuster Ozempic ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.

WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence. The ...

Semaglutide, the same compound that’s in Ozempic, is part of a class of medications known as glucagon-like peptide 1 (GLP-1) ...

U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's ...

Skye Bioscience (NASDAQ: SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space.

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...